Found 522 clinical trials
Cyclophosphamide Added to Standard Immunosuppressive Therapy With Eltrombopag as Front-line Therapy in Patients With Severe Aplastic Anemia
moderate-dose cyclophosphamide for severe aplastic anemia.
- 0 views
- 14 Aug, 2023
- 1 location
Efficacy Evaluation of an ODF Iron Supplement vs an Iron Supplement in Capsules in Subjects With Mild Anemia
The aim of the study is to evaluate the efficacy of a new iron supplement with orodispersible formulation vs an iron supplement in capsules in subjects with mild anemia.
- 0 views
- 24 Aug, 2023
- 1 location
Postoperative Replacement of Intraoperative Iron Losses (POREIIL)
By performing a randomized, blinded placebo controlled exploratory trial we speculate that replacement of perioperative, bleeding-induced iron losses with ferric carboxymaltose immediately after the surgical procedure can replenish iron with increased hemoglobin levels and reduce the amount of pRBCs transfused in the postoperative period (30 days post surgery).
- 0 views
- 19 Apr, 2022
- 1 location
Intravenous Gammaglobulin for Sickle Cell Pain Crises
The purpose of this study is to determine whether intravenous immune globulin is safe and effective in the acute treatment of pain crises in sickle cell disease.
- 41 views
- 07 Nov, 2020
- 1 location
Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly (SAA)
anemia treated for the first time. The design was: cyclosporine 3 mg/kg orally in two divided doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum
- 0 views
- 10 Jul, 2022
- 1 location
The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA
This study was a single-arm, multicenter, phase Π clinical study. Patients admitted to the enrollment unit center with a confirmed diagnosis of TDNSAA/VSAA/SAA, treated with IST (p/r-ATG+CSA) in combination with TPO-RA (including eltrombopta or hydtrombopta) for at least 3 months with no hematologic response at 6-month follow-up, and who were …
- 0 views
- 07 Oct, 2022
- 1 location
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (TransIT)
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular
- 0 views
- 16 Sep, 2023
- 28 locations
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with
- 0 views
- 30 Aug, 2023
- 1 location
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT). Hereditary Hemorrhagic
- 0 views
- 10 Jul, 2021
- 1 location
Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia (LGL)
patients suffering from T/NK LGL leukemia with severe neutropenia or neutropenia associated with infections, and/or anemia requiring transfusions, and/or auto-immune associated disease to
- 36 views
- 16 Sep, 2023
- 49 locations